Web Exclusives

Combined acalabrutinib, venetoclax, and obinutuzumab have shown favorable efficacy and tolerability in untreated patients in an ongoing phase 2 study.

The need to protect patients and healthcare workers from contracting COVID-19 has resulted in many changes to how hospital care is delivered.

Recent data suggest that patients with CLL who received treatment with a BTK inhibitor had a rate of developing a second cancer over twice as high as that expected in the general population.

The social isolation of the COVID-19 pandemic has left those with cancer feeling more left out than ever. Finding companionship and building close relationships, whether in person or virtually, is essential to overall well-being.

On World Cancer Day and every day, CONQUER magazine is dedicated to amplifying the voices of patients with cancer, survivors, caregivers, oncology care teams, and all those involved in the fight against cancer.

Targeted therapies continue to change the treatment landscape, improving outcomes beyond traditional chemoimmunotherapy.

Although most employers are not passing costs to employees, the COVID-19 pandemic has raised uncertainty throughout the entire healthcare system.

An analysis of 4 studies finds that acalabrutinib does not increase the risk of developing heart problems for patients with CLL.